MAGGIE MACIAS: Open Payments
NPI 1972203404 · CORINTH, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$450 in 19 payments from 8 companies in 2025. Trend: 2023 $0 · 2024 $249 · 2025 $450
Food & beverage: $450
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 8 | $152 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $120 |
| Lilly USA, LLC | 2 | $34 |
| Novo Nordisk Inc | 2 | $33 |
| Amgen Inc. | 2 | $31 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $30 |
| GlaxoSmithKline, LLC. | 2 | $30 |
| Esperion Therapeutics, Inc. | 1 | $20 |
Products named: Kerendia, FARXIGA, AIRSUPRA, JARDIANCE, CAPLYTA, TRELEGY ELLIPTA, NEXLETOL, OTEZLA.
Industry payments across MS — which companies pay providers there.
